Nocebo hyperalgesia in patients with fibromyalgia and healthy controls - An experimental investigation of conditioning and extinction processes at baseline and one-month follow-up

Merve Karacaoglu; Kaya J Peerdeman; Mattijs E Numans; Martha R Stolk; Simone Meijer; Regine Klinger; Dieuwke S Veldhuijzen; Henriët van Middendorp; Andrea W M Evers

doi:10.1016/j.jpain.2023.05.003

Nocebo hyperalgesia in patients with fibromyalgia and healthy controls - An experimental investigation of conditioning and extinction processes at baseline and one-month follow-up

Standard

Nocebo hyperalgesia in patients with fibromyalgia and healthy controls - An experimental investigation of conditioning and extinction processes at baseline and one-month follow-up. / Karacaoglu, Merve; Peerdeman, Kaya J; Numans, Mattijs E; Stolk, Martha R; Meijer, Simone; Klinger, Regine; Veldhuijzen, Dieuwke S; van Middendorp, Henriët; Evers, Andrea W M.

In: J PAIN, Vol. 24, No. 9, 09.2023, p. 1696-1711.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Karacaoglu, M, Peerdeman, KJ, Numans, ME, Stolk, MR, Meijer, S, Klinger, R, Veldhuijzen, DS, van Middendorp, H & Evers, AWM 2023, 'Nocebo hyperalgesia in patients with fibromyalgia and healthy controls - An experimental investigation of conditioning and extinction processes at baseline and one-month follow-up', J PAIN, vol. 24, no. 9, pp. 1696-1711. https://doi.org/10.1016/j.jpain.2023.05.003

APA

Karacaoglu, M., Peerdeman, K. J., Numans, M. E., Stolk, M. R., Meijer, S., Klinger, R., Veldhuijzen, D. S., van Middendorp, H., & Evers, A. W. M. (2023). Nocebo hyperalgesia in patients with fibromyalgia and healthy controls - An experimental investigation of conditioning and extinction processes at baseline and one-month follow-up. J PAIN, 24(9), 1696-1711. https://doi.org/10.1016/j.jpain.2023.05.003

Vancouver

Karacaoglu M, Peerdeman KJ, Numans ME, Stolk MR, Meijer S, Klinger R et al. Nocebo hyperalgesia in patients with fibromyalgia and healthy controls - An experimental investigation of conditioning and extinction processes at baseline and one-month follow-up. J PAIN. 2023 Sep;24(9):1696-1711. https://doi.org/10.1016/j.jpain.2023.05.003

Bibtex

@article{041a0c34cc1f4239a37f40be3dece037,

title = "Nocebo hyperalgesia in patients with fibromyalgia and healthy controls - An experimental investigation of conditioning and extinction processes at baseline and one-month follow-up",

abstract = "Nocebo effects are adverse treatment outcomes that are not ascribed to active treatment components. Potentially, their magnitude might be higher in patients with chronic pain compared to healthy controls since patients likely experience treatment failure more frequently. The current study investigated group differences in the induction and extinction of nocebo effects on pressure pain at baseline (N = 69) and 1-month follow-up (N = 56) in female patients with fibromyalgia and matched healthy controls. Nocebo effects were first experimentally induced via classical conditioning combined with instructions on the pain-increasing function of a sham transcutaneous electrical nerve stimulation device, then decreased via extinction. One month later, the same procedures were repeated to explore their stability. Results suggest that nocebo effects were induced in the healthy control group during baseline and follow-up. In the patient group, nocebo effects were only induced during follow-up, without clear group differences. Extinction was only observed during baseline in the healthy control group. Further comparisons of nocebo effects and extinction indicated no significant changes across sessions, possibly suggesting their overall magnitudes were stable over time and across groups. In conclusion, contrary to our expectations, patients with fibromyalgia did not have stronger nocebo hyperalgesia; instead, they might be less responsive to nocebo manipulations than healthy controls. PERSPECTIVE: The current study is the first to investigate group differences in experimentally manipulated nocebo hyperalgesia between chronic pain and healthy populations at baseline and 1-month follow-up. Since nocebo effects are common in clinical settings, their investigation in different populations is essential to explain and minimize their adverse effects during treatment.",

author = "Merve Karacaoglu and Peerdeman, {Kaya J} and Numans, {Mattijs E} and Stolk, {Martha R} and Simone Meijer and Regine Klinger and Veldhuijzen, {Dieuwke S} and {van Middendorp}, Henri{\"e}t and Evers, {Andrea W M}",

note = "Copyright {\textcopyright} 2023. Published by Elsevier Inc.",

year = "2023",

month = sep,

doi = "10.1016/j.jpain.2023.05.003",

language = "English",

volume = "24",

pages = "1696--1711",

journal = "J PAIN",

issn = "1526-5900",

publisher = "Churchill Livingstone",

number = "9",

}

RIS

TY - JOUR

T1 - Nocebo hyperalgesia in patients with fibromyalgia and healthy controls - An experimental investigation of conditioning and extinction processes at baseline and one-month follow-up

AU - Karacaoglu, Merve

AU - Peerdeman, Kaya J

AU - Numans, Mattijs E

AU - Stolk, Martha R

AU - Meijer, Simone

AU - Klinger, Regine

AU - Veldhuijzen, Dieuwke S

AU - van Middendorp, Henriët

AU - Evers, Andrea W M

PY - 2023/9

Y1 - 2023/9

N2 - Nocebo effects are adverse treatment outcomes that are not ascribed to active treatment components. Potentially, their magnitude might be higher in patients with chronic pain compared to healthy controls since patients likely experience treatment failure more frequently. The current study investigated group differences in the induction and extinction of nocebo effects on pressure pain at baseline (N = 69) and 1-month follow-up (N = 56) in female patients with fibromyalgia and matched healthy controls. Nocebo effects were first experimentally induced via classical conditioning combined with instructions on the pain-increasing function of a sham transcutaneous electrical nerve stimulation device, then decreased via extinction. One month later, the same procedures were repeated to explore their stability. Results suggest that nocebo effects were induced in the healthy control group during baseline and follow-up. In the patient group, nocebo effects were only induced during follow-up, without clear group differences. Extinction was only observed during baseline in the healthy control group. Further comparisons of nocebo effects and extinction indicated no significant changes across sessions, possibly suggesting their overall magnitudes were stable over time and across groups. In conclusion, contrary to our expectations, patients with fibromyalgia did not have stronger nocebo hyperalgesia; instead, they might be less responsive to nocebo manipulations than healthy controls. PERSPECTIVE: The current study is the first to investigate group differences in experimentally manipulated nocebo hyperalgesia between chronic pain and healthy populations at baseline and 1-month follow-up. Since nocebo effects are common in clinical settings, their investigation in different populations is essential to explain and minimize their adverse effects during treatment.

AB - Nocebo effects are adverse treatment outcomes that are not ascribed to active treatment components. Potentially, their magnitude might be higher in patients with chronic pain compared to healthy controls since patients likely experience treatment failure more frequently. The current study investigated group differences in the induction and extinction of nocebo effects on pressure pain at baseline (N = 69) and 1-month follow-up (N = 56) in female patients with fibromyalgia and matched healthy controls. Nocebo effects were first experimentally induced via classical conditioning combined with instructions on the pain-increasing function of a sham transcutaneous electrical nerve stimulation device, then decreased via extinction. One month later, the same procedures were repeated to explore their stability. Results suggest that nocebo effects were induced in the healthy control group during baseline and follow-up. In the patient group, nocebo effects were only induced during follow-up, without clear group differences. Extinction was only observed during baseline in the healthy control group. Further comparisons of nocebo effects and extinction indicated no significant changes across sessions, possibly suggesting their overall magnitudes were stable over time and across groups. In conclusion, contrary to our expectations, patients with fibromyalgia did not have stronger nocebo hyperalgesia; instead, they might be less responsive to nocebo manipulations than healthy controls. PERSPECTIVE: The current study is the first to investigate group differences in experimentally manipulated nocebo hyperalgesia between chronic pain and healthy populations at baseline and 1-month follow-up. Since nocebo effects are common in clinical settings, their investigation in different populations is essential to explain and minimize their adverse effects during treatment.

U2 - 10.1016/j.jpain.2023.05.003

DO - 10.1016/j.jpain.2023.05.003

M3 - SCORING: Journal article

C2 - 37196928

VL - 24

SP - 1696

EP - 1711

JO - J PAIN

JF - J PAIN

SN - 1526-5900

IS - 9

ER -